L-Ornithine L-Aspartate in pharma franchise in Maharashtra

L-Ornithine L-Aspartate in PCD pharma franchise in Bhopal

L-Ornithine L-Aspartate in top pharma company in Allahabad

L-Ornithine L-Aspartate in pcd pharma supplier in Howrah

L-Ornithine L-Aspartate in phama franchise company in India
L-Ornithine L-Aspartate in phama distributor in Ranchi

Home/Products /l-ornithine-l-aspartate-3gm-powders-sachet-shots

Hepalogy Sachet

Composition : L-Ornithine L-Aspartate (3gm) Sachet

Dosage Form : Sachet

Packaging Type : pack

Packaging : 5gmx10

Price : ₹177/-

Please Contact For Best Price

Hepalogy Sachet contains L-Ornithine L-Aspartate (3g), a potent compound that supports liver health by promoting detoxification and optimizing ammonia metabolism. This formulation is particularly effective in managing hepatic disorders and improving symptoms associated with liver dysfunction. L-Ornithine L-Aspartate works by enhancing the urea cycle, which helps eliminate excess ammonia from the body. It is often used in the treatment of hepatic encephalopathy, fatty liver disease, and other liver conditions.

The unique blend of L-Ornithine and L-Aspartate assists in regenerating damaged liver cells and boosts energy levels by aiding in the metabolism of amino acids. Hepalogy Sachet offers a convenient and fast-absorbing form, making it suitable for individuals requiring liver function support due to conditions such as alcohol-induced liver damage, viral hepatitis, or cirrhosis.

This supplement not only improves liver health but also alleviates symptoms like fatigue, confusion, and digestive discomfort associated with poor liver function. It plays a significant role in reducing the burden on the liver by accelerating the detoxification process and supporting overall metabolic efficiency.

Read More

About the Product

Hepalogy Sachet contains L-Ornithine L-Aspartate (3g), a potent compound that supports liver health by promoting detoxification and optimizing ammonia metabolism. This formulation is particularly effective in managing hepatic disorders and improving symptoms associated with liver dysfunction. L-Ornithine L-Aspartate works by enhancing the urea cycle, which helps eliminate excess ammonia from the body. It is often used in the treatment of hepatic encephalopathy, fatty liver disease, and other liver conditions.

The unique blend of L-Ornithine and L-Aspartate assists in regenerating damaged liver cells and boosts energy levels by aiding in the metabolism of amino acids. Hepalogy Sachet offers a convenient and fast-absorbing form, making it suitable for individuals requiring liver function support due to conditions such as alcohol-induced liver damage, viral hepatitis, or cirrhosis.

This supplement not only improves liver health but also alleviates symptoms like fatigue, confusion, and digestive discomfort associated with poor liver function. It plays a significant role in reducing the burden on the liver by accelerating the detoxification process and supporting overall metabolic efficiency.

Common side effects include nausea, mild abdominal discomfort, or diarrhea. Rarely, allergic reactions may occur.

Indicated for hepatic encephalopathy, liver dysfunction, and hyperammonemia. It supports detoxification and promotes liver regeneration.

Use under the guidance of a healthcare professional. Do not exceed the recommended dosage. Consult your doctor before use if you have pre-existing medical conditions or are taking other medications.

Store in a cool, dry place below 25°C. Protect from light and moisture. Keep out of reach of children.

Get in Touch

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our Successful network today.

Quick Navigation

1500+ Products

Our Divisions

All Therapeutics

Disclaimer: Pharma Insights are based on operational standards as of March 2026. All territories are subject to availability and Revised Schedule M compliance.